Embecta Corp rises on beating earnings estimates
** Embecta Corp's shares EMBC.O up 9.4% at $31.07
** Diabetes care co reports Q1 sales of $275.7 mln, higher
than analysts' estimates of $262.9 mln - Refinitiv IBES data
** Q1 profit came in at $0.96 per share, beating estimates
of $0.52
** Co announces quarterly dividend of $0.15 per share
** EMBC down ~35% since its IPO last year
(Reporting by Khushi Mandowara in Bengaluru)
((Khushi.Mandowara@thomsonreuters.com;))
Recent news on Embecta
See all newsEmbecta Corp. reports results for the quarter ended June 30 - Earnings Summary
Brief: Embecta Reports Third Quarter Fiscal 2026 Financial Results
Brief: Embecta Outlook FY Adjusted EPS USD 0.27 Vs. IBES Estimate USD 1.59
U.S. STOCKS ON THE MOVE-TransDigm, Rhythm Pharmaceuticals, Intel
U.S. STOCKS ON THE MOVE-TransDigm, Rhythm Pharmaceuticals, Intel